evobrutinib

Small moleculeexperimental

Clinical trial activity

18 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
10
Phase 2
8
Phase 3
4
Phase 4
0

Earliest trial started Jul 31, 2016 (NCT02784106)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2019

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1
Mol. weight
429.52 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • m2951

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07214935Phase 1Nov 8, 2022Merck KGaA
NCT05245396Phase 1Feb 2, 2022Merck KGaA
NCT05248945Phase 1Jan 13, 2022Merck KGaA
NCT05064488Phase 1Oct 4, 2021Merck KGaA
NCT04697511Phase 1Jan 11, 2021Merck KGaA
NCT04546789Phase 1Sep 30, 2020Merck KGaA
NCT04338061Phase 3Jun 15, 2020Merck KGaA, Merck Serono
NCT04338022Phase 3Jun 15, 2020Merck KGaA, Merck Serono
NCT04314024Phase 1Mar 23, 2020Merck KGaA
NCT04032158Phase 3Aug 19, 2019Merck KGaA, Merck Serono
NCT04032171Phase 3Aug 19, 2019Merck KGaA, Merck Serono
NCT03934502Phase 1Apr 15, 2019Merck KGaA
NCT03725072Phase 1Oct 30, 2018Merck KGaA
NCT03436394Phase 1Mar 21, 2018Merck KGaA
NCT03233230Phase 2Sep 18, 2017Merck KGaA, Merck Serono
NCT02975349Phase 2Apr 6, 2017Merck KGaA, Merck Serono
NCT02975336Phase 2Jan 4, 2017Merck KGaA, Merck Serono
NCT02784106Phase 2Jul 31, 2016Merck KGaA, Merck Serono
Showing 18 of 18 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Merck KGaAFor profit181232016
Merck SeronoFor profit8622016
2 organizations
Page 1 / 1